The trajectory of here companies tied to Sildenafil's history presents a intricate investment scenario . While the initial boom generated substantial returns , generic competition have significantly diminished sales . Investing in associated pharmaceutical companies now requires a careful assessment of patent protection , evolving patient shifts ,